Cargando…
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma
Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcinoma (UTUC) has a higher response rate to ICIs. The stratification...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706581/ https://www.ncbi.nlm.nih.gov/pubmed/36451860 http://dx.doi.org/10.7150/thno.77281 |
_version_ | 1784840535514546176 |
---|---|
author | Liang, Yuan Tan, Yezhen Guan, Bao Guo, Bin Xia, Mancheng Li, Juan Shi, Yue Yu, Zihui Zhang, Qi Liu, Di Yang, Xiaopeng Hao, Junfeng Gong, Yanqing Shakeel, Muhammad Zhou, Liqun Ci, Weimin Li, Xuesong |
author_facet | Liang, Yuan Tan, Yezhen Guan, Bao Guo, Bin Xia, Mancheng Li, Juan Shi, Yue Yu, Zihui Zhang, Qi Liu, Di Yang, Xiaopeng Hao, Junfeng Gong, Yanqing Shakeel, Muhammad Zhou, Liqun Ci, Weimin Li, Xuesong |
author_sort | Liang, Yuan |
collection | PubMed |
description | Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcinoma (UTUC) has a higher response rate to ICIs. The stratification of patients most likely to benefit from ICI therapy remains a major clinical challenge. Methods: In this study, we performed the first single-cell RNA sequencing (scRNA-seq) study of 13 surgical tissue specimens from 12 patients with UTUC. The key results were validated by the analysis of two independent cohorts with bulk RNA-seq data for UCB (n = 404) and UTUC (n = 158) and one cohort of patients with metastatic urothelial carcinoma (mUC) who were treated with atezolizumab (n = 348). Results: Using scRNA-seq, we observed a higher proportion of tumor-infiltrating immune cells in locally advanced UTUC. Similar prognostically relevant intrinsic basal and luminal-like epithelial subtypes were found in both UTUC and UCB, although UTUC is predominantly of the luminal subtype. We also discovered that immunosuppressive macrophages and exhausted T-cell subpopulations were enriched in the basal subtype and showed enhanced interactions. Furthermore, we developed a gene expression signature (Macro-C3 score) capturing the immunosuppressive macrophages that better predicts outcomes than the currently established subtypes. We also developed a computational method to model immune evasion, and the Macro-C3 score predicted therapeutic response of mUC treated with first-line anti-PD-L1 inhibitors in patients with lower basal scores. Conclusions: Overall, the distinct microenvironment and Macro-C3 score provide an explanation for ICI efficacy in urothelial carcinoma and reveal new candidate regulators of immune evasion, suggesting potential therapeutic targets for improving antitumor immunity in the basal subtype. |
format | Online Article Text |
id | pubmed-9706581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-97065812022-11-29 Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma Liang, Yuan Tan, Yezhen Guan, Bao Guo, Bin Xia, Mancheng Li, Juan Shi, Yue Yu, Zihui Zhang, Qi Liu, Di Yang, Xiaopeng Hao, Junfeng Gong, Yanqing Shakeel, Muhammad Zhou, Liqun Ci, Weimin Li, Xuesong Theranostics Research Paper Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to urothelial carcinoma of the bladder (UCB), upper tract urothelial carcinoma (UTUC) has a higher response rate to ICIs. The stratification of patients most likely to benefit from ICI therapy remains a major clinical challenge. Methods: In this study, we performed the first single-cell RNA sequencing (scRNA-seq) study of 13 surgical tissue specimens from 12 patients with UTUC. The key results were validated by the analysis of two independent cohorts with bulk RNA-seq data for UCB (n = 404) and UTUC (n = 158) and one cohort of patients with metastatic urothelial carcinoma (mUC) who were treated with atezolizumab (n = 348). Results: Using scRNA-seq, we observed a higher proportion of tumor-infiltrating immune cells in locally advanced UTUC. Similar prognostically relevant intrinsic basal and luminal-like epithelial subtypes were found in both UTUC and UCB, although UTUC is predominantly of the luminal subtype. We also discovered that immunosuppressive macrophages and exhausted T-cell subpopulations were enriched in the basal subtype and showed enhanced interactions. Furthermore, we developed a gene expression signature (Macro-C3 score) capturing the immunosuppressive macrophages that better predicts outcomes than the currently established subtypes. We also developed a computational method to model immune evasion, and the Macro-C3 score predicted therapeutic response of mUC treated with first-line anti-PD-L1 inhibitors in patients with lower basal scores. Conclusions: Overall, the distinct microenvironment and Macro-C3 score provide an explanation for ICI efficacy in urothelial carcinoma and reveal new candidate regulators of immune evasion, suggesting potential therapeutic targets for improving antitumor immunity in the basal subtype. Ivyspring International Publisher 2022-11-14 /pmc/articles/PMC9706581/ /pubmed/36451860 http://dx.doi.org/10.7150/thno.77281 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Liang, Yuan Tan, Yezhen Guan, Bao Guo, Bin Xia, Mancheng Li, Juan Shi, Yue Yu, Zihui Zhang, Qi Liu, Di Yang, Xiaopeng Hao, Junfeng Gong, Yanqing Shakeel, Muhammad Zhou, Liqun Ci, Weimin Li, Xuesong Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
title | Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
title_full | Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
title_fullStr | Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
title_full_unstemmed | Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
title_short | Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
title_sort | single-cell atlases link macrophages and cd8(+) t-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706581/ https://www.ncbi.nlm.nih.gov/pubmed/36451860 http://dx.doi.org/10.7150/thno.77281 |
work_keys_str_mv | AT liangyuan singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT tanyezhen singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT guanbao singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT guobin singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT xiamancheng singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT lijuan singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT shiyue singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT yuzihui singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT zhangqi singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT liudi singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT yangxiaopeng singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT haojunfeng singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT gongyanqing singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT shakeelmuhammad singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT zhouliqun singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT ciweimin singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma AT lixuesong singlecellatlaseslinkmacrophagesandcd8tcellsubpopulationstodiseaseprogressionandimmunotherapyresponseinurothelialcarcinoma |